Immune cell capable of automatically secreting IL-15 and anti-PD1 fusion protein

A fusion protein and immune cell technology, applied in the field of autocrine fusion protein immune cells, can solve the problems of malignant tumors that are prone to metastasis, difficult to cure, and easy to relapse, and achieve the effect of precise killing effect, low recurrence rate and high safety

Pending Publication Date: 2021-07-13
SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD
6 Cites 1 Cited by

AI-Extracted Technical Summary

Problems solved by technology

Among them, malignant tumors are extremely difficult to cure due to their suscepti...
View more

Method used

The present invention provides a kind of immune cell of self-secretion IL-15 and anti-PD1 fusion protein, uses the immune cell secreted IL-15 and anti-PD1 fusion protein through gene editing, to improve the activity of immune cell and For tumor killing effect, immune cells ...
View more

Abstract

The invention relates to the technical field of biological cells, in particular to an immune cell capable of automatically secreting IL-15 and anti-PD1 fusion protein, and the immune cell subjected to gene editing is used for secreting the IL-15 and anti-PD1 fusion protein so as to improve the activity of the immune cell and the killing effect on tumors. The immune cell capable of automatically secreting IL-15 and anti-PD1 fusion protein comprises the fusion protein is expressed in series according to the sequence of anti-PD1, G4S * 4 Linker, IL-15N72D, G4S * 4 Linker and IL-15RaSu, and the cell used for expressing the fusion protein and influenced by the autosecretion fusion protein and subjected to gene editing. According to the invention, the IL-15 and IL15Ra super kinetin and the anti-PD1 fusion protein are combined, and the CART cells successfully secrete the fusion protein, so that the proliferation ability, the anti-apoptosis ability and the tumor killing ability of the CarT cells are enhanced, the killing effect is accurate, the safety is higher, the tumor is not easy to relapse, and the life quality of patients is improved.

Application Domain

Polypeptide with localisation/targeting motifImmunoglobulin superfamily +7

Technology Topic

Biology cellMolecular biology +6

Image

  • Immune cell capable of automatically secreting IL-15 and anti-PD1 fusion protein
  • Immune cell capable of automatically secreting IL-15 and anti-PD1 fusion protein
  • Immune cell capable of automatically secreting IL-15 and anti-PD1 fusion protein

Examples

  • Experimental program(1)
  • Effect test(1)

Example Embodiment

[0032] In order to facilitate understanding of the present invention, the present invention will be described more fully below. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that a thorough and complete understanding of the present disclosure is provided.
[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terms used herein in the description of the present invention are for the purpose of describing specific embodiments only, and are not intended to limit the present invention.
[0034] The technical solutions of the patent of the present invention will be clearly and completely described below. Obviously, the described embodiments are part of the embodiments of the present invention, but not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative efforts shall fall within the protection scope of the present invention.
[0035] The present invention provides an immune cell that autocrines IL-15 and anti-PD1 fusion protein, and uses gene-edited immune cells to secrete IL-15 and anti-PD1 fusion protein, so as to improve the activity of immune cells and improve the anti-tumor effect. Killing effect, immune cells that autocrine IL-15 and anti-PD1 fusion proteins include: fusion proteins expressed in series according to the sequence of anti-PD1, G4S*4 Linker, IL-15N72D, G4S*4 Linker and IL-15RaSu, and the expression The fusion protein and the gene-edited cells affected by the autocrine fusion protein.
[0036]Immune cells themselves do not express the fusion proteins mentioned above. In order for immune cells to secrete the fusion proteins, they need to undergo gene editing. In addition, cells used for tumor treatment such as CarT/CarNK/TCR-T/IPS are already genetically engineered. Edited and then made to secrete fusion proteins are still edited immune cells, so they are collectively referred to as gene-edited immune cells here. The autocrine IL-15 and anti-PD1 fusion protein immune cells of the present invention combine IL-15 and IL15Ra hyperkinesin and anti-PD1 fusion protein, and obtain chimeric antigen receptor T cells that successfully secrete the fusion protein (Chimeric antigen receptor CART).
[0037] anti-PD1 is anti-PD1 VL and/or anti-PD1 VH.
[0038] In one embodiment, the immune cells express a chimeric antigen receptor (CAR). The expression of the chimeric antigen receptor can be a CAR targeting one target, or a CAR targeting two targets or multiple targets.
[0039] In one embodiment, the target of the chimeric antigen receptor may be the idiotype of the anti-CLDN18.2 antibody.
[0040] The target of the chimeric antigen receptor can also be one or more of the idiotypes CLDN18.2, GPC3, HER2, TAA, GD2, MSLN, EGFR, NY-ESO-1, MUCl, PSMA and EBV.
[0041] The binding region of the chimeric antigen receptor and target can be scFv and/or Fab. In one embodiment, the structure of the scFv region in the chimeric antigen receptor structure can be replaced by any single-chain antibody, single-chain variable fragment (scFv) and Fab fragment of any target.
[0042] Chimeric antigen receptors contain a leader sequence, an scFv that recognizes tumor-associated antigens, a hinge and transmembrane domain, an intracellular co-stimulatory domain, and the intracellular activation signal CD3ζ.
[0043] scFv is the scFv of anti-idiotype antibody; hinge region and transmembrane domain are CD28 or CD8 hinge region and transmembrane domain; intracellular costimulatory domain is CD28 or CD137 (4-1BB) or ICOS intracellular costimulatory structure area.
[0044] The binding region of the chimeric antigen receptor and the target can be a bispecific antibody that binds to one target, or a bispecific antibody that binds two targets, or two or more chimeric antigen receptors are formed across the membrane respectively. and identify different targets.
[0045] The division between immune cells and autocrine IL-15 and anti-PD1 fusion protein is a protein cleavage functional element. The protein cleavage functional element can be T2A, P2A, E2A, F2A or IRES.
[0046] In one embodiment, the gene transfer method of immune cells is: lentivirus, retrovirus, common plasmid vector, episomal vector, nano-delivery system, electrotransduction, transposon or other delivery systems.
[0047] In one embodiment, the immune cells are T cells, NK cells, NKT cells, macrophages, gamma-delta T cells, TIL cells, TCR-T cells or other tumor killer cells.
[0048] Immune cells that autocrine IL-15 and anti-PD1 fusion protein can be made into preparations, and the preparations are pharmaceutically acceptable carriers, diluents or excipients. Administration of the formulations of the present invention can be carried out in any convenient manner, including by nebulization, injection, swallowing, infusion, implantation or transplantation. The formulation can be used for the prevention and/or treatment of solid tumors.
[0049] The autocrine IL-15 and anti-PD1 fusion protein immune cells of the present invention express CAR, which specifically recognizes the idiotype of the anti-autoantibody; the hyperkinesin and anti-PD1 fusion protein combined with IL-15 and IL15Ra, and The fusion protein is successfully secreted by the CART cells to enhance the proliferation ability, anti-apoptosis ability and tumor killing ability of the CarT cells; in addition, the immune cells of the present invention can specifically kill and secrete the fusion protein of IL-15 and anti-PD1; and The killing effect is precise, the safety is higher, it is not easy to recur, and the quality of life of patients is improved.
[0050] The following is a description of specific embodiments.
[0051] In the following examples, the preparation of CarT and the secretion of IL-15 and anti-PD1 fusion protein from T cells in peripheral blood is used as an example. The preparation method and functional verification of immune cells include the following steps:
[0052] 1) Structural design of fusion protein;
[0053] 2) Construct secreted CART cells and conduct in vitro functional tests;
[0054] 3) In vivo functional test of CART cells secreting fusion protein.
[0055] 1) Structural design of fusion protein
[0056] According to the sequence of hIL15, hIL15Ra, anti-PD1, according to figure 1 The middle structure was designed as the fusion protein structure in A#~D#, and it was designed into CarT-CLDN18.2, where 1# was the control CarT, and 2#~4# were secreted CarT.
[0057] Wherein, the amino acid sequence of hIL15 is: METDTLLLWVLLLWVPGSTGNWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS.
[0058] The amino acid sequence of hIL15Ra is: ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIR.
[0059] Anti-PD1 VH amino acid sequence is: QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS.
[0060] Anti-PD1 VL amino acid sequence is: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK.
[0061] The amino acid sequence of Linker is: GSSSSGSSSSGSSSSGSSSS.
[0062] 2) Construction of secreted CART cells and in vitro functional tests
[0063] Construction of secreted CART cells and in vitro functional tests include the following steps:
[0064] S100: Cell Line Culture
[0065] The base sequence expressing CLDN18.2 was cloned into the backbone of PHBLV lentiviral vector and placed under the promoter of EF1α (EF-1α) to form PHBLV-EF1α-CLDN18.2, PHBLV-EF1α-CLDN18.2, slow The viral envelope plasmid pMD2.G (Addgene, Plasmid#12259) and the lentiviral packaging plasmid psPAX2 (Addgene Plasmid#12260) were transferred into 293T using Lipofectamine3000 to prepare a complete lentiviral expression vector;
[0066] The virus supernatant was collected at 48h and 72h, and concentrated by ultracentrifugation (Merck Millipore); the concentrated virus could be used to infect HGC-27, and finally the HGC-27 cell line overexpressing CLDN18.2 was obtained and named as HGC-27- The detection results of CLDN18.2 and HGC-27-CLDN18.2 cells expressing CLDN18.2 are as follows figure 2 shown.
[0067] S200: Isolation of peripheral blood PBMC and expansion of T cells
[0068] Mononuclear cells were isolated from donor peripheral blood, subjected to density gradient centrifugation using ficol, and enriched for T cells using a T cell sorting kit (CD3 MicroBeads, human-lyophilized, 130-097-043) using conjugated anti-CD3 /anti-CD28 magnetic beads activate the culture and expansion of T cells;
[0069] The medium used TexMACS GMP Medium (Miltenyi Biotec, 170-076-309), containing 10% FBS, 2mM L-glutamine, 100IU/ml rhIL2, all cells were placed at 37°C, 5% CO 2 Cultured in a constant temperature incubator.
[0070] 1) The proteins in the B#~D# sequences in the structural design of the fusion protein were expressed and purified by the CHO protein expression system as a positive control standard for ELISA detection of protein secretion in 1#~4#, and the CarT culture supernatant was collected. Serum protein secretion data such as image 3 As shown, CarT-CLDN18.2-IL15/Ra, CarT-CLDN18.2-antiPD1, CarT-CLDN18.2-15&PD1 can secrete proteins normally, and have substantially the same protein secretion efficiency.
[0071] CarT was prepared by lentiviral packaging. The positive rate and phenotype results are shown in Figure 5 and Image 6. The obtained CarT proliferation is as follows Figure 4 As shown, CarT-CLDN18.2-15&PD1 has more excellent cell proliferation ability.

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.

Similar technology patents

A layering and partially filling coal mining method of thick seams

InactiveCN104832178Aimprove securityLower filling costs
Owner:CHINA UNIV OF MINING & TECH

Nano metal silver antibiotic paint and its preparing method

InactiveCN1616559Aimprove security
Owner:RESEARCH INSTITUTE OF TSINGHUA UNIVERSITY IN SHENZHEN

Classification and recommendation of technical efficacy words

  • improve security

Pesticide micro-capsule granules and preparation method thereof

InactiveCN102100229Alow toxicityimprove security
Owner:联合国南通农药剂型开发中心 +1

Method for achieving user authentication by utilizing camera

InactiveCN103678984Aimprove securityGuaranteed picture quality
Owner:湖北微模式科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products